Chronic Lymphocytic Leukemia (CLL)

TG Therapeutics Tumbles 40% on Partial Clinical Trial Hold

Edward Kim | |

Shares of TG Therapeutics (TGTX) got slammed Thursday after CEO Michael Weiss disclosed that the FDA had placed a partial hold on the company's Phase 3 trial  lost 40.5% of their value Thursday on nevaluating the investigational U2 combination (UKONIQ® (umbralisib) and ublituximab) compared to the control arm of obinutuzumab plus chlorambucil and that the FDA imposed a partial clinical hold on select studies of U2 and its components for chronic lymphocytic leukemia (CLL) ...

Sponsored Financial Content

Market Movers